GlassScriptPhysician profile
Megan N Avery
NPI 1861010506
$1,684.90
in general payments reported to CMS, 2019-2025
20 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $489 · 2022: $633 · 2023: $278 · 2024: $182 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $235.74 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $211.24 | 2021-2022 | |
| Abbvie INC. | $152.39 | 2021-2023 | |
| Lundbeck LLC | $120.34 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $117.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $111.17 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $106.58 | 2022 | |
| Exeltis, USA INC. | $103.35 | 2025 | Slynd, Twirla |
| Supernus Pharmaceuticals, INC. | $94.97 | 2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $90.45 | 2022-2023 | Rexulti |
| Genzyme Corporation | $79.60 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $46.59 | 2023-2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.43 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.47 | 2023 | Trintellix |
| Alkermes, INC. | $29.48 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $29.22 | 2021 | |
| Bausch Health US, LLC | $21.38 | 2021 | |
| Almatica Pharma LLC | $17.86 | 2022 | |
| Axsome Therapeutics, INC. | $17.32 | 2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.